Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RDHL | US
-0.28
-3.36%
Healthcare
Biotechnology
30/06/2023
17/10/2024
8.21
8.34
8.40
8.16
RedHill Biopharma Ltd. a specialty biopharmaceutical company primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204 which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva) an SK2 selective inhibitor which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia in Phase 2 study to treat advanced unresectable cholangiocarcinoma and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107 which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104 which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv Israel.
View LessLow Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
49.8%1 month
53.4%3 months
5207.2%6 months
3711.6%-
1.43K
168.19
0.66
0.07
0.30
0.96
-
-20.94M
10.51M
10.51M
-
-328.46
-
-28.40
-1.71K
0.64
2.46
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.60
Range1M
3.17
Range3M
12.22
Rel. volume
0.37
Price X volume
67.23K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Jaguar Health Inc | JAGX | Biotechnology | 1.23 | 11.37M | 0.00% | 0.26 | 176.14% |
Common Stock | ADXN | Biotechnology | 10.6 | 11.33M | 0.47% | n/a | 0.25% |
Immuron Limited | IMRN | Biotechnology | 1.97 | 11.22M | -1.99% | n/a | 1.37% |
Evogene Ltd | EVGN | Biotechnology | 2.14 | 11.15M | -16.08% | n/a | 26.41% |
TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 0.599 | 10.78M | -11.79% | 0.00 | 17.19% |
Sensei Biotherapeutics Inc | SNSE | Biotechnology | 0.4237 | 10.66M | -7.69% | n/a | 9.67% |
Alterity Therapeutics Limited | ATHE | Biotechnology | 1.2 | 10.49M | -4.00% | n/a | 1.15% |
GlycoMimetics Inc | GLYC | Biotechnology | 0.1585 | 10.22M | 1.02% | n/a | 2.24% |
SNTI | SNTI | Biotechnology | 2.15 | 9.84M | -1.83% | n/a | 80.96% |
KPRX | KPRX | Biotechnology | 3.31 | 9.83M | -2.65% | 0.21 | 0.25% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.30 | 0.53 | Cheaper |
Ent. to Revenue | 0.96 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 168.19 | 15.30 | Expensive |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 5,207.24 | 72.92 | Riskier |
Debt to Equity | 0.66 | -1.24 | Expensive |
Debt to Assets | 0.07 | 0.25 | Cheaper |
Market Cap | 10.51M | 3.78B | Emerging |